Study of Ipilimumab in the Immune System

Clinical trial NCT01715077 · COMPLETED

Trial details

NCT number: NCT01715077
Sponsor: University Health Network, Toronto
Status: COMPLETED
Phase: Not Applicable
Study type: INTERVENTIONAL

Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma

Start date: 2012-10-01
Primary completion: 2017-10-01
Enrollment: 4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.